Paul R Edick Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Paul R Edick.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Paul R Edick. Paul R Edick is Director in PDL BIOPHARMA, INC. ($PDLI) and Director in NEWLINK GENETICS CORP ($NLNK) and See Remarks in XERIS PHARMACEUTICALS INC ($XERS) and Director in Sucampo Pharmaceuticals, Inc. ($SCMP) and Director in Milestone Pharmaceuticals Inc. ($MIST) and Director in Neos Therapeutics, Inc. ($NEOS) and Director in Iterum Therapeutics plc ($ITRM).
Latest Insider Trading Transactions of Paul R Edick
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ITRM, NLNK, MIST, NEOS, PDLI, SCMP, XERS
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 01 2021 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Option Exercise | A | 5.08 | 400,000 | 2,032,000 | 400,000 | |
| Feb 01 2021 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Grant | A | 0.00 | 225,000 | 0 | 636,134 | 411.1 K to 636.1 K (+54.73 %) |
| Dec 10 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 4.06 | 10,000 | 40,551 | 411,134 | 401.1 K to 411.1 K (+2.49 %) |
| Dec 10 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 4.06 | 10,000 | 40,551 | 411,134 | 401.1 K to 411.1 K (+2.49 %) |
| Jun 08 2020 | MIST | Milestone Pharmace ... | Edick Paul R | Director | Option Exercise | A | 3.74 | 15,000 | 56,100 | 15,000 | |
| May 11 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 3.00 | 33,000 | 99,000 | 401,134 | 368.1 K to 401.1 K (+8.96 %) |
| Mar 02 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Grant | A | 0.00 | 185,000 | 0 | 368,134 | 183.1 K to 368.1 K (+101.02 %) |
| Mar 02 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Grant | A | 0.00 | 185,000 | 0 | 368,134 | 183.1 K to 368.1 K (+101.02 %) |
| Feb 18 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 4.15 | 20,000 | 83,000 | 183,134 | 163.1 K to 183.1 K (+12.26 %) |
| Feb 04 2020 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Payment of Exercise | F | 6.37 | 9,801 | 62,432 | 163,134 | 172.9 K to 163.1 K (-5.67 %) |
| Nov 27 2019 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 8.55 | 17,935 | 153,283 | 172,935 | 155 K to 172.9 K (+11.57 %) |
| Nov 27 2019 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 8.55 | 17,935 | 153,283 | 172,935 | 155 K to 172.9 K (+11.57 %) |
| May 29 2019 | ITRM | Iterum Therapeutic ... | Edick Paul R | Director | Option Exercise | M | 0.00 | 6,154 | 0 | 0 | |
| May 29 2019 | ITRM | Iterum Therapeutic ... | Edick Paul R | Director | Buy | M | 0.00 | 6,154 | 0 | 31,390 | 25.2 K to 31.4 K (+24.39 %) |
| Mar 12 2019 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | P | 9.12 | 30,000 | 273,585 | 155,000 | 125 K to 155 K (+24.00 %) |
| Feb 01 2019 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Option Exercise | A | 13.88 | 200,000 | 2,776,000 | 200,000 | |
| Feb 01 2019 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Grant | A | 0.00 | 125,000 | 0 | 125,000 | 0 to 125 K |
| Aug 27 2018 | ITRM | Iterum Therapeutic ... | Edick Paul R | Director | Buy | P | 10.44 | 500 | 5,219 | 25,236 | 24.7 K to 25.2 K (+2.02 %) |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Option Exercise | C | 0.00 | 23,922 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Option Exercise | C | 0.00 | 23,922 | 0 | 0 | |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | C | 0.00 | 13,430 | 0 | 13,430 | 0 to 13.4 K |
| Jun 27 2018 | XERS | XERIS PHARMACEUTIC ... | Edick Paul R | See Remarks | Buy | C | 0.00 | 13,430 | 0 | 13,430 | 0 to 13.4 K |
| Jun 12 2018 | PDLI | PDL BIOPHARMA, INC ... | Edick Paul R | Director | Grant | A | 2.76 | 54,348 | 150,000 | 214,563 | 160.2 K to 214.6 K (+33.92 %) |
| May 30 2018 | ITRM | Iterum Therapeutic ... | Edick Paul R | Director | Option Exercise | C | 0.00 | 1,591 | 0 | 0 | |
| May 30 2018 | ITRM | Iterum Therapeutic ... | Edick Paul R | Director | Option Exercise | C | 0.00 | 4,050 | 0 | 0 | |
| May 30 2018 | ITRM | Iterum Therapeutic ... | Edick Paul R | Director | Option Exercise | C | 0.00 | 15,913 | 0 | 0 | |
| May 30 2018 | ITRM | Iterum Therapeutic ... | Edick Paul R | Director | Buy | C | 0.00 | 1,591 | 0 | 24,736 | 23.1 K to 24.7 K (+6.87 %) |
| May 30 2018 | ITRM | Iterum Therapeutic ... | Edick Paul R | Director | Buy | C | 0.00 | 4,050 | 0 | 23,145 | 19.1 K to 23.1 K (+21.21 %) |
| May 30 2018 | ITRM | Iterum Therapeutic ... | Edick Paul R | Director | Buy | C | 0.00 | 15,913 | 0 | 19,095 | 3.2 K to 19.1 K (+500.09 %) |
| May 29 2018 | ITRM | Iterum Therapeutic ... | Edick Paul R | Director | Option Exercise | A | 0.00 | 6,154 | 0 | 6,154 | |
| Jun 12 2017 | PDLI | PDL BIOPHARMA, INC ... | Edick Paul R | Director | Grant | A | 2.47 | 60,729 | 150,001 | 160,215 | 99.5 K to 160.2 K (+61.04 %) |
| Jun 05 2017 | SCMP | Sucampo Pharmaceut ... | Edick Paul R | Director | Option Exercise | A | 10.30 | 10,000 | 103,000 | 10,000 | |
| Jun 05 2017 | SCMP | Sucampo Pharmaceut ... | Edick Paul R | Director | Grant | A | 0.00 | 5,130 | 0 | 14,930 | 9.8 K to 14.9 K (+52.35 %) |
| May 16 2017 | NLNK | NEWLINK GENETICS C ... | Edick Paul R | Director | Option Exercise | A | 17.42 | 13,309 | 231,843 | 13,309 | |
| Aug 11 2016 | NLNK | NEWLINK GENETICS C ... | Edick Paul R | Director | Option Exercise | A | 10.78 | 4,783 | 51,561 | 4,783 | |
| Aug 11 2016 | NLNK | NEWLINK GENETICS C ... | Edick Paul R | Director | Option Exercise | A | 10.78 | 17,773 | 191,593 | 17,773 | |
| Aug 03 2016 | SCMP | Sucampo Pharmaceut ... | Edick Paul R | Director | Grant | A | 0.00 | 14,700 | 0 | 14,700 | 0 to 14.7 K |
| Jul 05 2016 | NEOS | Neos Therapeutics, ... | Edick Paul R | Director | Option Exercise | A | 9.63 | 14,777 | 142,303 | 14,777 | |
| Jun 03 2016 | PDLI | PDL BIOPHARMA, INC ... | Edick Paul R | Director | Grant | A | 3.52 | 71,023 | 250,001 | 99,486 | 28.5 K to 99.5 K (+249.53 %) |
| Sep 08 2015 | PDLI | PDL BIOPHARMA, INC ... | Edick Paul R | Director | Grant | A | 5.27 | 28,463 | 150,000 | 28,463 | 0 to 28.5 K |
| May 04 2015 | NLNK | NEWLINK GENETICS C ... | Edick Paul R | Director | Option Exercise | A | 44.60 | 3,643 | 162,478 | 3,643 | |
| May 04 2015 | NLNK | NEWLINK GENETICS C ... | Edick Paul R | Director | Grant | A | 0.00 | 1,962 | 0 | 7,906 | 5.9 K to 7.9 K (+33.01 %) |
| May 05 2014 | NLNK | NEWLINK GENETICS C ... | Edick Paul R | Director | Option Exercise | A | 21.23 | 8,331 | 176,867 | 8,331 | |
| May 05 2014 | NLNK | NEWLINK GENETICS C ... | Edick Paul R | Director | Grant | A | 0.00 | 2,944 | 0 | 5,944 | 3 K to 5.9 K (+98.13 %) |
| Jan 06 2014 | NLNK | NEWLINK GENETICS C ... | Edick Paul R | Director | Grant | A | 0.00 | 3,000 | 0 | 3,000 | 0 to 3 K |
| May 10 2013 | NLNK | NEWLINK GENETICS C ... | Edick Paul R | Director | Option Exercise | A | 14.71 | 12,000 | 176,520 | 12,000 | |
| Jan 23 2012 | NLNK | NEWLINK GENETICS C ... | Edick Paul R | Director | Option Exercise | A | 6.87 | 2,381 | 16,357 | 2,381 | |
| Nov 14 2011 | NLNK | NEWLINK GENETICS C ... | Edick Paul R | Director | Option Exercise | A | 7.00 | 11,904 | 83,328 | 11,904 |
Page: 1